{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:19:17Z","timestamp":1793661557719,"version":"4.5.1"},"reference-count":10,"publisher":"Scientific Scholar","content-domain":{"domain":["ruralneuropractice.com"],"crossmark-restriction":true},"short-container-title":["JNRP"],"abstract":"<jats:p>This study describes the profile of children diagnosed with posterior reversible encephalopathy syndrome (PRES) in the pediatric hematology oncology unit and highlights the clinical features of PRES in immunosuppressed children. This retrospective study included 10 children diagnosed with PRES with a mean age of 6.8 years. Acute lymphoblastic leukemia was the most common primary diagnosis followed by post-hematopoietic stem cell transplant patients. Most cases of PRES occurred within one month of treatment initiation. Hypertension was noted in all at the time of diagnosis. Neuroimaging revealed bilateral lesions with parietal and occipital lobe involvement being the most common. All patients received corticosteroids as part of treatment for primary diagnosis. Controlling blood pressure was critical in managing PRES. Consideration of PRES as a clinical possibility in pediatric hematology oncology unit in children presenting with symptoms such as headache, seizures, and visual disturbances will aid in early diagnosis after ruling out other causes of these symptoms.<\/jats:p>","DOI":"10.25259\/jnrp_390_2023","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T06:58:47Z","timestamp":1707807527000},"page":"365-369","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Posterior reversible encephalopathy syndrome in immunocompromised children \u2013 A single-center study from South India"],"prefix":"10.25259","volume":"15","author":[{"given":"Sudeep","family":"Gaddam","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kodandapani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhita","family":"Mani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaarani","family":"Jayaraman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Nikitha","family":"Abirami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"10.25259\/JNRP_390_2023\/ref-1","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1097\/j.pbj.0000000000000147","article-title":"Etiology and clinical characteristics of pediatric non-neoplastic posterior reversible encephalopathy: Systematic review","volume":"7","author":"Jord\u00e3o","year":"2022","journal-title":"Porto Biomed J"},{"key":"10.25259\/JNRP_390_2023\/ref-2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/jdn.10184","article-title":"Clinical features and prognostic analysis of posterior reversible encephalopathy syndrome in children","volume":"82","author":"Deng","year":"2022","journal-title":"Int J Dev Neurosci"},{"key":"10.25259\/JNRP_390_2023\/ref-3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MPH.0000000000002153","article-title":"Posterior reversible encephalopathy syndrome: Incidence and clinical characteristics in children with cancer","volume":"44","author":"Sommers","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.25259\/JNRP_390_2023\/ref-4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00130","article-title":"Posterior reversible encephalopathy syndrome in pediatric cancer: Clinical and radiologic findings","volume":"4","author":"Khan","year":"2018","journal-title":"J Glob Oncol"},{"key":"10.25259\/JNRP_390_2023\/ref-5","doi-asserted-by":"publisher","first-page":"E709","DOI":"10.1097\/MPH.0000000000002367","article-title":"Posterior reversible encephalopathy syndrome in the setting of asparaginase-associated pancreatitis in 2 pediatric patients with acute leukemia","volume":"44","author":"Scheuermann","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.25259\/JNRP_390_2023\/ref-6","doi-asserted-by":"publisher","first-page":"678890","DOI":"10.3389\/fped.2021.678890","article-title":"Management and clinical outcome of posterior reversible encephalopathy syndrome in pediatric oncologic\/hematologic diseases: A PRES subgroup analysis with a large sample size","volume":"9","author":"Hun","year":"2021","journal-title":"Front Pediatr"},{"key":"10.25259\/JNRP_390_2023\/ref-7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/annonc\/mdq382","article-title":"Posterior reversible encephalopathy syndrome in childhood cancer","volume":"22","author":"de Laat","year":"2011","journal-title":"Ann Oncol"},{"key":"10.25259\/JNRP_390_2023\/ref-8","doi-asserted-by":"publisher","first-page":"e27594","DOI":"10.1002\/pbc.27594","article-title":"Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Clinical characteristics, risk factors, course, and outcome of disease","volume":"66","author":"Anastasopoulou","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.25259\/JNRP_390_2023\/ref-9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/joah.joah_153_20","article-title":"Posterior reversible encephalopathy syndrome after high dose cytarabine in pediatric acute myeloid leukemia","volume":"12","author":"Gupta","year":"2021","journal-title":"J Appl Hematol"},{"key":"10.25259\/JNRP_390_2023\/ref-10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/10428194.2020.1832658","article-title":"Patterns, risk factors and outcome predictors of posterior reversible encephalopathy syndrome in pediatric cancer patients","volume":"62","author":"Hafez","year":"2021","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Neurosciences in Rural Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ruralneuropractice.com\/posterior-reversible-encephalopathy-syndrome-in-immunocompromised-children-a-single-center-study-from-south-india\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ruralneuropractice.com\/posterior-reversible-encephalopathy-syndrome-in-immunocompromised-children-a-single-center-study-from-south-india\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T08:35:27Z","timestamp":1715070927000},"score":1,"resource":{"primary":{"URL":"https:\/\/ruralneuropractice.com\/posterior-reversible-encephalopathy-syndrome-in-immunocompromised-children-a-single-center-study-from-south-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":10,"alternative-id":["10.25259\/JNRP_390_2023"],"URL":"https:\/\/doi.org\/10.25259\/jnrp_390_2023","relation":{},"ISSN":["0976-3155","0976-3147"],"issn-type":[{"value":"0976-3155","type":"electronic"},{"value":"0976-3147","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"article-number":"365"}}